BRIEF published on 04/01/2026 at 07:35, 7 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 7 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 7 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 8 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 2 months 18 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
PRESS RELEASE published on 01/20/2026 at 18:30, 2 months 18 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 3 months 28 days ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
PRESS RELEASE published on 12/10/2025 at 11:25, 3 months 28 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates recommendation to BUY for MaaT Pharma SACA with a target price of €17 following positive phase 3 trial results for Xervyteg presented at ASH Annual Meeting 2025 First Berlin Equity Research Buy Recommendation ASH Annual Meeting Xervyteg MaaT Pharma SACA
BRIEF published on 11/21/2025 at 11:27, 4 months 16 days ago Crossing Thresholds at MAAT PHARMA Voting Rights Capital Increase Crossing Thresholds MaaT Pharma Invus Public Equities
BRIEF published on 11/19/2025 at 11:16, 4 months 18 days ago MaaT Pharma Secures Capital to Support Commercialization Efforts Capital Increase MaaT Pharma Biotech Investment Xervyteg AGvHD Treatment
Published on 04/08/2026 at 02:50, 4 hours 47 minutes ago Panther Minerals Announces Appointment of Rick Mah to Board of Directors
Published on 04/08/2026 at 01:35, 6 hours 2 minutes ago Polaris Renewable Energy Announces Q1 2026 Investor Call Details
Published on 04/08/2026 at 00:40, 6 hours 57 minutes ago Relevant Gold Announces Initial Closing of Strategic Financing
Published on 04/08/2026 at 00:10, 7 hours 27 minutes ago Trans Canada Gold Completes the Acquisition of the Harrison Lake District Scale Gold Property and First Tranche of the Non-Brokered Private Placement
Published on 04/08/2026 at 00:00, 7 hours 37 minutes ago Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Published on 04/08/2026 at 07:00, 37 minutes ago Redcare Pharmacy in Q1: non-Rx growth rebounds in Germany, while strong Rx growth continues.
Published on 04/08/2026 at 06:30, 1 hour 7 minutes ago R&S Group publishes annual and non-financial reports 2025
Published on 04/08/2026 at 01:30, 6 hours 6 minutes ago DFC Funding Positions PELA to Deliver Critical Antimony Supply to U.S. and Allied Markets
Published on 04/07/2026 at 16:32, 15 hours 5 minutes ago Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
Published on 04/07/2026 at 17:57, 13 hours 39 minutes ago Peugeot Invest publishes its 2025 Universal Registration Document
Published on 04/07/2026 at 17:45, 13 hours 52 minutes ago ENGIE accelerates the deployment of battery storage with nearly 400 MW of new projects in Europe
Published on 04/07/2026 at 17:38, 13 hours 58 minutes ago Reporting on share buyback transactions carried out between March 30 and April 2, 2026
Published on 04/07/2026 at 17:35, 14 hours 2 minutes ago Disclosure of the number of shares and the total number of voting rights as of March 31, 2026
